연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3195. Proposal of nomograms to predict clinical outcomes in patients with ampulla of Vater cancer based on the Korea-Japan collaborative study.
Kim, H. S., Kim, W., Endo, I., Jang, J. Y., Kim, H., Song, K. B., Hwang, D. W., Kang, C. M., Hwang, H. K., Park, S. J., Han, S. S., Yoon, Y. S., Do Yang, J., Amano, R., Yamazoe, S., Yanagimoto, H., Ajiki, T., Ohtsuka, M., Suzuki, D., ... Park, J. S.
J Hepatobiliary Pancreat Sci . 2023 Mar;30(3):360-373.
Link
3194. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant
Neven P, Fasching PA, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Zarate JP, Wang Y, Chakravartty A, Wang C, Slamon DJ.
Breast Cancer Res 2023 Aug 31;25(1):103.
Link
3193. Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study
Bae SJ, Kim HJ, Kim HA, Ryu JM, Park S, Lee EG, Im SA, Jung Y, Park MH, Park KH, Kang SH, Park E, Kim SY, Lee MH, Kim LS, Lee A, Noh WC, Gwark S, Kim S, Jeong J
Int J Surg 2023 Nov 23 [Epub ahead of print]
Link
3192. Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355
Cescon DW, Schmid P, Rugo HS, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Haiderali A, Zhou X, Guo Z, Nguyen AM, Cortes J.
J Natl Cancer Inst 2023 Dec 9:djad240. [Epub ahead of print]
Link
3191. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study
Schmid P, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Tamura K, Testa L, Witzel I, Ohtani S, Turner N, Zambelli S, Harbeck N, Andre F, Dent R, Mejia JA, Zhou X, Haiderali A, Nguyen AM, Cortes J, Winer EP.
Eur J Cancer 2023 Dec:195:113393
Link
3190. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Takahashi M, Cortés J, Dent R, Pusztai L, McArthur H, Kümmel S, Denkert C, Park YH, Im SA, Ahn JH, Mukai H, Huang CS, Chen SC, Kim MH, Jia L, Li XT, Tryfonidis K, Karantza V, Iwata H, Schmid P
JAMA Netw Open
2023 Nov 1;6(11):e2342107.
Link
3189. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, de Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S
Clin Cancer Res 2024 Jan 5;30(1):50-62.
Link
3188. The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results
Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V.
Future Oncol 2023 Nov 2. [Epub ahead of print]
Link
3187. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
Soo Yeon Baek, Woo Chul Noh, Sei-Hyun Ahn, Hyun-Ah Kim, Jai Min Ryu, Seung Il Kim, Eun-Gyeong Lee, Seock-Ah Im, Yongsik Jung, Min Ho Park, Kyong Hwa Park, Su Hwan Kang, Joon Jeong, Eunhwa Park, Sung Yong Kim, Min Hyuk Lee, Lee Su Kim, Woosung Lim
; Seonok Kim, MSc18 ; and Hee Jeong Kim, MD, PhD
J Clin Oncol 2023 Nov 1;41(31):4864-4871.
Link
3186. Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers
Nikas IP, Lim S, Im S-A, Lee K-H, Lee D-W, Lee H, Ryu HS
Pathobiology 2023 Oct 10. [Epub ahead of print]
Link